B cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus
erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare …

B cell hyperactivity is a hallmark of the complex autoimmune disease systemic lupus
erythematosus (SLE), which has justified drug development focusing on B cell altering …

Objectives Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus
(SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic …

Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab
is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been …

OBSErve Germany was the first observational study of belimumab as add-on treatment for
systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively …

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, with varied course
and symptoms. Its etiology is very complex and not clearly understood. There is growing …

Background Circulating T follicular helper (cTfh) and T peripheral helper (Tph)
subpopulations are shown to be higher in systemic lupus erythematosus (SLE) patients and …

Objectives Lupus nephritis (LN) is a major cause of morbidity in patients with systemic lupus
erythematosus (SLE). B cells have a central role in the pathogenesis of SLE. B lymphocyte …

Objective Accumulating evidence supports an impaired health‐related quality of life (HRQ
oL) in patients with systemic lupus erythematosus (SLE). We investigated the effects of 2 …

Although the putative therapeutic options for patients with systemic lupus erythematosus
(SLE) are steadily increasing, refractory disease is indeed a major challenge to many …